Advertisement

Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart

  • Filomena de Nigris
    Affiliations
    Department of General Pathology, Division of Clinical Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine and Surgery, II University of Naples, Complesso S. Andrea delle Dame, Via L. de Crecchio 7, 80138 Naples, Italy
    Search for articles by this author
  • Monica Rienzo
    Affiliations
    Department of General Pathology, Division of Clinical Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine and Surgery, II University of Naples, Complesso S. Andrea delle Dame, Via L. de Crecchio 7, 80138 Naples, Italy
    Search for articles by this author
  • Concetta Schiano
    Affiliations
    Department of General Pathology, Division of Clinical Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine and Surgery, II University of Naples, Complesso S. Andrea delle Dame, Via L. de Crecchio 7, 80138 Naples, Italy
    Search for articles by this author
  • Carmela Fiorito
    Affiliations
    IRCCS Multimedica Milan, Italy
    Search for articles by this author
  • Amelia Casamassimi
    Affiliations
    Department of General Pathology, Division of Clinical Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine and Surgery, II University of Naples, Complesso S. Andrea delle Dame, Via L. de Crecchio 7, 80138 Naples, Italy
    Search for articles by this author
  • Claudio Napoli
    Correspondence
    Corresponding author: Tel.: +39 81 5667567; fax: +39 81 450169.
    Affiliations
    Department of General Pathology, Division of Clinical Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine and Surgery, II University of Naples, Complesso S. Andrea delle Dame, Via L. de Crecchio 7, 80138 Naples, Italy
    Search for articles by this author
Published:January 15, 2008DOI:https://doi.org/10.1016/j.ejca.2007.12.010

      Abstract

      Nebivolol is a cardioselective beta-blocker (BB) currently used for the treatment of hypertension. It has mild vasodilating properties attributed to its interaction with the L-arginine/nitric oxide pathway, a property not shared by other BBs. Carvedilol is a nonselective ß-adrenergic receptor antagonist that also blocks α1-adrenergic receptors and is a potent antioxidant. Anthracyclines (ANTs), daunorubicin and doxorubicin, are commonly used in the treatment of several tumours, but their cardiac toxicity prevents their use at maximum myelotoxic doses, representing an important problem. In this study, we have evaluated the role of these BBs administered in combination with ANTs (daunorubicin and doxorubicin) on a reduction in cardiac toxicity. The combination of BB and ANTs has reduced the release of GSSG and GSH; in particular, co-treatment with nebivolol to ANTs has shown a significant reduction. The total integrated creatine kinase and troponin T activities were improved by BB and ANTs co-treatment. A significant reduction of their release was observed when hearts were treated with nebivolol. Cardiac tissue activity of gluthatione reductase was not significant and similar among experimental groups. In contrast, gluthatione peroxidise, Mn-superoxide dismutase and nitrite/nitrate release were increased after co-treatment with nebivolol. Finally, three parameters have been used to evaluate the cardiac toxicity of ANTs: the left ventricular pressure developed under a constant perfusion pressure (LVDP), the rate of variation of this parameter during systole (contractility) (LV/dt)max and during diastole (relaxation) (LV(dP/dt)min. Combination with BB has shown a reduction in cardiac toxicity; in particular, nebivolol has exerted the most significant cardioprotective effect.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Minotti G.
        • Menna P.
        • Salvatorelli E.
        • Cairo G.
        • Gianni L.
        Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
        Pharmacol Rev. 2004; 56: 185-229
        • Hasinoff B.B.
        • Hellmann K.
        • Herman E.H.
        • Ferrans V.J.
        Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
        Curr Med Chem. 1998; 5: 1-28
        • Matsui H.
        • Morishima I.
        • Numaguchi Y.
        • Toki Y.
        • Okumura K.
        • Hayakawa T.
        Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
        Life Sci. 1999; 65: 1265-1274
        • Kalay N.
        • Basar E.
        • Ozdogru I.
        • et al.
        Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
        J Am Coll Cardiol. 2006; 48: 2258-2262
        • Napoli C.
        • De Nigris F.
        • Cicala C.
        • et al.
        Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning.
        Am J Physiol. 2002; 282: H2004-H2010
        • Napoli C.
        • Cicala C.
        • Wallace J.L.
        • et al.
        Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart.
        Proc Natl Acad Sci U S A. 2000; 97: 3678-3683
        • Poun P.
        • Bonoron-Adele S.
        • Gouverneur G.
        • Tariosse L.
        • Besse P.
        • Robert J.
        Development of the model of rat isolated perfused heart for the evaluation of anthracyline cardiotoxicity and its circumvention.
        Br J Pharmacol. 1996; 117: 1593-1599
        • Platel D.
        • Pouna P.
        • Bonoron-Adele S.
        • Robert J.
        Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.
        Anticancer Drugs. 1999; 10: 671-676
        • Robert J.
        Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls.
        Cell Biol Toxicol. 2007; 23: 27-37
        • Ignarro L.J.
        • Cirino G.
        • Casini A.
        • Napoli C.
        Nitric oxide as a signaling molecule in the vascular system: an overview.
        J Cardiovasc Pharmacol. 1999; 34: 879-886
        • Mason R.P.
        • Kalinowski L.
        • Jacob R.F.
        • Jacoby A.M.
        • Malinski T.
        Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans.
        Circulation. 2005; 112: 3795-3801
        • Gielen W.
        • Cleophas T.J.
        • Agrawal R.
        Nebivolol: a review of its clinical and pharmacological characteristics.
        Int J Clin Pharmacol Ther. 2006; 44: 344-357
        • Ghio S.
        • Magrini G.
        • Serio A.
        • et al.
        SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy.
        Eur Heart J. 2006; 27: 562-568
        • Napoli C.
        • Williams-Ignarro S.
        • De Nigris F.
        • et al.
        Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice.
        Proc Natl Acad Sci U S A. 2004; 101: 8797-8802
        • Shan K.
        • Lincoff A.M.
        • Young J.B.
        Anthracycline-induced cardiotoxicity.
        Ann Intern Med. 1996; 125: 47-58
        • Herman E.H.
        • Zhang J.
        • Lipshultz S.E.
        • et al.
        Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
        J Clin Oncol. 1999; 17: 2237-2243
        • Carreira R.S.
        • Monteiro P.
        • Gon Alves L.M.
        • Providencia L.A.
        Carvedilol: just another Beta-blocker or a powerful cardioprotector?.
        Cardiovasc Hematol Disord Drug Targets. 2006; 6: 257-266
        • Mukai Y.
        • Yoshida T.
        • Nakaike R.
        • et al.
        Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.
        Intern Med. 2004; 43: 1087-1088
        • Weber M.A.
        The role of the new beta-blockers in treating cardiovascular disease.
        Am J Hypertens. 2005; 18: 169S-176S
        • Goldhammer E.
        • Maor I.
        • Shnitzer S.
        • Lanir A.
        • Abinader E.G.
        The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
        J Cardiovasc Med. 2007; 8: 453-456
        • Pedersen M.E.
        • Cockcroft J.R.
        The vasodilatory beta-blockers.
        Curr Hypertens Rep. 2007; 9: 269-277
        • de Boer R.A.
        • Voors A.A.
        • van Veldhuisen D.J.
        Nebivolol: third-generation beta-blockade.
        Expert Opin Pharmacother. 2007; 8: 1539-1550
        • McMahon C.J.
        • Murchan H.
        • Prendiville T.
        • Burch M.
        Parvovirus B19 infection associated with dilated cardiomyopathy in patients with previous anthracycline exposure.
        Pediatr Cardiol. 2007; 28: 394-395